<DOC>
	<DOCNO>NCT00456053</DOCNO>
	<brief_summary>The purpose study test safety efficacy FG-2216 treatment patient renal anemia receive erythropoietin dialysis .</brief_summary>
	<brief_title>A Randomized Study Safety Efficacy FG-2216 Subjects With Renal Anemia Not Requiring Dialysis Not Receiving Recombinant Human Erythropoietin</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Stage 3 4 chronic kidney disease appropriate hemoglobin level Neovascular age relate macular degeneration require treatment Macular edema proliferative retinopathy diabetic subject , require treatment Any history malignancy Therapy recombinant erythropoietin red blood cell transfusion within 4 week Renal Transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Renal Anemia</keyword>
	<keyword>Renal Failure</keyword>
	<keyword>Kidney Disease</keyword>
	<keyword>Human EPO</keyword>
</DOC>